BD Medical (Becton, Dickinson and Company) has partnered with Medtronic to launch a new insulin pump infusion set, which is being developed using BD FlowSmart technology. The insulin infusion set with BD FlowSmart technology was developed in collaboration with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust to improve the treatment of type I diabetes.
Under the deal, Medtronic will take responsibility to commercialize the infusion set, while BD will manufacture the product. Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
The insulin infusion set with BD FlowSmart technology features a unique side-ported catheter designed to improve insulin flow, potentially reducing the number of flow interruptions “ defined as a continuous rise in inline pressure lasting at least 30 minutes. Without triggering a pump occlusion alarm, these events are known as silent occlusions, and because pump users may be unaware of these lapses in insulin flow, they could lead to unexplained hyperglycemia in some people on pump therapy. This infusion set also features the smallest insertion needle (30-gauge) currently available, which is designed to reduce insertion pain.
“Medtronic is committed to advancing innovation across the entire insulin pump system, including infusion sets, to improve outcomes and expand options to satisfy different patient needs, body types and lifestyles,” said Annette Bruls, Vice-President and General Manager, Diabetes Service and Solutions at Medtronic. “Our partnering with diabetes technology leaders, such as BD, will give more people with diabetes access to these innovations so they can enjoy greater freedom and better health.”
“By increasing the reach and availability of this technology, we have an opportunity to enhance the use of insulin pump therapy by providing potentially more consistent insulin delivery and fewer flow interruptions. This technology is an extension of BD’s long-standing commitment to deliver injection solutions, and builds on previous BD research that has advanced the science and understanding of insulin delivery as well as patient comfort,” said Kenneth Miller, Worldwide President, BD Medical-Diabetes Care.